LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

NOTICE OF THE 2025 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2025 annual general meeting (the "**2025 AGM**") of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the "**Company**") will be held at 10:30 a.m. on Friday, May 22, 2026 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC, to consider and, if appropriate, approve, with or without amendments, the following resolutions. Unless otherwise specified, capitalized terms used in this notice shall have the same meanings as defined in the circular of the Company dated April 23, 2026 (the "**Circular**").

ORDINARY RESOLUTIONS

(1) To consider and approve the 2025 work report of the Board;

(2) To consider and approve the 2025 work report of the Board of Supervisors;

(3) To consider and approve the 2025 annual report;

(4) To consider and approve the 2025 independent auditor's report;

(5) To consider and approve the 2026 financial budget plan;

(6) To consider and approve the reports on remuneration of Directors and Supervisors for 2025 and 2026;

(7) To consider and approve the re-appointment of BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as the Company's auditor for 2026, until the conclusion of the 2026 annual general meeting of the Company, and to authorize the Board to determine its remuneration;

(8) To consider and approve the profit distribution plan of the Company for the year of 2025;

(9) To consider and approve the proposal to elect Ms. Wang Yong (王泳) as a supervisor of the second session of the Board of Supervisors.

SPECIAL RESOLUTIONS

(10) To consider and approve the granting of a general mandate to the Board to issue shares of the Company (the "**Shares**"):

"**THAT**:

(a) The Board be and is hereby granted, during the Relevant Period (as defined in paragraph (b) below), a general and unconditional mandate to issue, allot and/or deal with additional Shares (including any sale or transfer of treasury Shares), and to make or grant offers, agreements or options which would or might require the Shares to be issued, allotted and/or dealt with, subject to the following conditions:

(i) such mandate shall not extend beyond the Relevant Period save that the Board may during the Relevant Period make or grant offers, agreements or options which might require the exercise of such powers after the end of the Relevant Period;

(ii) the number of the Shares to be issued, allotted and/or deal with or agreed conditionally or unconditionally to be issued, allotted and/or dealt with by the Board shall not exceed 20% of its Shares (excluding any treasury Shares); and

(iii) the Board will only exercise its power under such mandate in accordance with the Company Law of the PRC and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time) or applicable laws, rules and regulations of other government or regulatory bodies and only if all necessary ratifications, approvals, or filings from the China Securities Regulatory Commission and/or other relevant PRC government authorities are obtained.

(b) For the purposes of this special resolution:

"Relevant Period" means the period from the passing of this special resolution until the earliest of:

(i) the conclusion of the next annual general meeting of the Company following the passing of this special resolution;

(ii) the expiration of the 12-month period following the passing of this special resolution; or

(iii) the date on which the authority granted to the Board as set out in this special resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting.

(c) Contingent on the Board resolving to issue the Shares pursuant to paragraph (a) of this special resolution, the Board be authorized to increase the registered capital of the Company to reflect the number of such shares authorized to be issued by the Company pursuant to paragraph (a) of this special resolution and to make such appropriate and necessary amendments to the articles of association of the Company as they think fit to reflect such increases in the registered capital of the Company and to take any other action and complete any formality required to effect the issuance of the Shares pursuant to paragraph (a) of this special resolution and the increase in the registered capital of the Company."

(11) To consider and, if thought fit, approve the grant of a general mandate to the Board to repurchase H Shares not exceeding 10% of the number of H Shares in issue (excluding treasury shares) on the date of the passing of this resolution:

"**THAT**

A. (i) subject to paragraph 11(A)(ii) of this resolution and in accordance with the relevant requirements of the Listing Rules, the Articles of Association and the applicable laws and regulations of the PRC, the exercise by the Board during the Relevant Period (as defined below) of all the powers of the Company to repurchase H Shares, be and is hereby generally and unconditionally approved;

(ii) the total number of H Shares to be repurchased by the Board pursuant to the approval granted in paragraph 11(A)(i) of this resolution shall not exceed 10% of the total number of H Shares in issue (excluding treasury shares) on the date of the passing of this resolution;

and for the purposes of this resolution:

"Relevant Period" means the period from the date of the passing of this resolution until whichever is the earliest of:

(a) the conclusion of the next annual general meeting of the Company;

(b) the expiration of the 12-month period after the passing of this resolution at the 2025 AGM; or

(c) the revocation or variation of the authority given to the Board under this resolution by passing of a special resolution of the Company in a general meeting.

B. Contingent on the Board resolving to repurchase H Shares pursuant to paragraph 11(A)(i) of this resolution, the Board be authorised to (i) formulate and implement the particular repurchase plan, including but not limited to the number of H Shares to be repurchased, the repurchase price (including price range), batches, number of shares, implementation period and repurchase period and other contents to be included in a particular repurchase plan as required by the relevant laws, regulations and other normative documents, as well as the relevant regulatory authorities and stock exchange of the place where the Shares are listed; (ii) open overseas stock accounts and handle the relevant foreign exchange approval and foreign exchange change registration procedures for foreign exchange registration (if necessary); (iii) notify the Company's creditors and publish announcements and obtain the necessary approvals or perform filing procedures in accordance with applicable laws, regulations and related requirements (if necessary); (iv) if there are new laws and regulations, or new policies of regulatory authorities, or changes in market conditions related to the repurchase of H Shares, unless the relevant laws and regulations or regulatory authorities or the provisions of the Articles of Association require re-voting at the general meeting and/or class meeting of shareholders, the Board may, in accordance with the relevant laws and regulations and the requirements of regulatory authorities, as well as market conditions and the actual situation of the Company, adjust the repurchase plan and continue to handle matters related to the repurchase of H Share; (v) decide whether to cancel the repurchased H Shares or hold them as treasury shares based on market conditions and the Company's capital management needs at the time of repurchase; and (vi) if it is decided to cancel the repurchased H Shares, deal with matters relating to the cancellation procedures and/or reduction of registered capital and/or change of shareholding structure, and to make corresponding amendments to the Articles of Association as appropriate."

Details of the above resolutions submitted to the 2025 AGM are set out in the Circular.

By Order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
April 23, 2026

As at the date of this notice, the Board comprises Ms. Chen Juan as an executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

Notes:

i. To determine the list of Shareholders entitled to attend the 2025 AGM, the register of members of the Company will be closed from Tuesday, May 19, 2026 to Friday, May 22, 2026 (both days inclusive), during which no transfer of Shares will be effected. Shareholders whose names appear on the Company's register of members on Friday, May 22, 2026 shall be entitled to attend and vote at the 2025 AGM. To be eligible to attend and vote at the 2025 AGM, all transfer documents shall be delivered, no later than 4:30 p.m. on Monday, May 18, 2026, to the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

ii. Each Shareholder entitled to attend and vote at the 2025 AGM may, by completing the form of proxy of the Company, appoint one or more proxies to attend and vote at the 2025 AGM on his/her/its behalf. A proxy need not be a Shareholder. With respect to any Shareholder who has appointed more than one proxy, such proxies may only exercise their voting rights in a poll.

iii. The form of proxy shall be signed by the appointer or his/her attorney duly authorized in writing or, in the case of a legal person, must be either executed under its common seal or under the hand of its director or attorney duly authorized.

iv. In order to be valid, the form of proxy must be deposited, at the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 24 hours prior to the holding of the 2025 AGM or any adjournment thereof. If the form of proxy is signed by another person under a power of attorney or other authorization documents given by the appointer, such power of attorney or other authorization documents shall be notarized. The notarized power of attorney or other authorization documents shall, together with the form of proxy, be deposited at the specified place at the time set out in such form of proxy. Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the 2025 AGM or any adjourned meetings should they so wish.

v. Shareholders shall produce their identity documents and supporting documents in respect of the Shares held when attending the 2025 AGM. If Shareholders appoint an authorized representative to attend the 2025 AGM, the authorized representative shall produce his/her identity documents and a notarially certified copy of the relevant authorization instrument signed by the board of directors or other authorized persons of the Shareholders or other notarially certified documents allowed by the Company. Proxies shall produce their identity documents and the form of proxy signed by the Shareholders or their authorized representative(s) when attending the 2025 AGM.

vi. The Company shall have the right to request the proxies attending the 2025 AGM on behalf of the Shareholders to produce their identity documents.

vii. In the case of joint Shareholders, the vote cast by the senior Shareholder, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholders, and for this purpose seniority shall be determined by the order in which the names of the relevant joint Shareholders stand on the register of members of the Company.

Pursuant to the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Therefore, the resolutions set out in the notice of the 2025 AGM will be taken by poll.

The H Share Registrar, Tricor Investor Services Limited, is located at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Tel: +852 2980 1333, Fax: +852 2810 8185.